Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2004

View Archived Issues

Utility of pramlintide demonstrated in recent diabetes trials

AstraZeneca claims three novel series of delta opioid agonists

New RUP3 receptor modulators and their use claimed by Arena

Novel CHK1 kinase inhibitors identified by Pfizer team

Pharmacopeia researchers describe new IL-8 receptor inhibitors

New c-Kit inhibitors under study at OSI

New peptides targeting tumor cells and their use claimed by Attenuon

CAT-354 to enter phase I study in U.K.

Graffinity Pharmaceuticals and MyoContract merge to form Santhera

Nucryst reports phase IIa results for NPI-32101 in atopic dermatitis

Aeolus cleared to begin phase I trials of AEOL-10150

Canadian approval for phase IIa study of MBI-3253

Subsequent offering period expires in Sanofi-Aventis offer for Aventis

U.S./Canadian pivotal study commences for icatibant in hereditary angioedema

New study evaluates effects of HCT-3012 vs. rofecoxib on blood pressure

Antineoplastons A10 and AS2-1 gain orphan drug status for brain stem glioma

Cellegesic NDA accepted for review

Avexa demerger approval

Pain Therapeutics completes enrollment in first phase III study of Oxytrex

Callisto licenses annamycin from M.D. Anderson

Toyama Chemical and GSK collaborate in antibacterial development

Glenmark files to advance GRC-3886 into phase I studies in U.K.

Clinical evidence supports the antidiabetic efficacy of MK-0431 in humans

Good safety profile found for EM-1421 in refractory head and neck cancer

Sitaxsentan improves performance of PAH patients failing bosentan therapy

L-2264 improves hyperglycemia, lipids in animal model of diabetes

CollaGenex highlights Q2 progress

Antigenics continued steady progress during second quarter

FR-183998 shows beneficial effects in porcine pancreas allotransplantation model

New, potent alphavbeta3 antagonists selected for clinical evaluation for osteoporosis at Merck

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...